- Home
- DDI vs GKOS Comparison
DDI vs GKOS Comparison
Compare DDI & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDI
- GKOS
- Stock Information
- Founded
- DDI 2008
- GKOS 1998
- Country
- DDI South Korea
- GKOS United States
- Employees
- DDI N/A
- GKOS 995
- Industry
- DDI EDP Services
- GKOS Medical/Dental Instruments
- Sector
- DDI Technology
- GKOS Health Care
- Exchange
- DDI Nasdaq
- GKOS Nasdaq
- Market Cap
- DDI N/A
- GKOS 5.1B
- IPO Year
- DDI 2021
- GKOS 2015
- Fundamental
- Price
- DDI $9.85
- GKOS $90.26
- Analyst Decision
- DDI Strong Buy
- GKOS Strong Buy
- Analyst Count
- DDI 4
- GKOS 13
- Target Price
- DDI $21.50
- GKOS $155.00
- AVG Volume (30 Days)
- DDI 23.5K
- GKOS 1.0M
- Earning Date
- DDI 05-07-2025
- GKOS 04-30-2025
- Dividend Yield
- DDI N/A
- GKOS N/A
- EPS Growth
- DDI 27.20
- GKOS N/A
- EPS
- DDI 2.31
- GKOS N/A
- Revenue
- DDI $315,157,843.00
- GKOS $383,481,000.00
- Revenue This Year
- DDI N/A
- GKOS $27.84
- Revenue Next Year
- DDI $2.43
- GKOS $27.99
- P/E Ratio
- DDI $4.27
- GKOS N/A
- Revenue Growth
- DDI 15.47
- GKOS 21.85
- 52 Week Low
- DDI $8.88
- GKOS $77.91
- 52 Week High
- DDI $18.21
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- DDI 49.84
- GKOS 41.57
- Support Level
- DDI $9.58
- GKOS $86.16
- Resistance Level
- DDI $10.10
- GKOS $94.55
- Average True Range (ATR)
- DDI 0.56
- GKOS 6.54
- MACD
- DDI 0.05
- GKOS 1.11
- Stochastic Oscillator
- DDI 70.80
- GKOS 54.51
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.